Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Ga68-Dolacga
- Development stage
- Unknown
- Lead developer
- National Atomic Research Institute
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Positron Emitters → Radiopharmaceuticals, Peptide-Drug Conjugates → Peptide Conjugates → Peptides, Small Molecules
- Administration
- Intravenous
01
Overview
Ga68-Dolacga is a radiopharmaceutical diagnostic agent used in positron emission tomography (PET) imaging, primarily developed for the evaluation of liver reserve function and tumor response in patients with hepatocellular carcinoma. It consists of a peptide chelated to gallium-68, a positron-emitting radionuclide. The agent is designed to target specific receptors or tissues within the liver, enabling functional imaging that can assess hepatic reserve before and after interventions such as proton therapy or surgery. Clinical studies have demonstrated its high liver-targeting properties and favorable safety profile[3][8]. The mechanism of action involves selective uptake by hepatic tissue, allowing quantitative assessment of regional liver function.
- Brand names
- Dolacga
- Other names
- Gallium Ga-68 DolacgaGa-68 DolacgaGa68 DolacgaGa 68 DolacgaGa68-Dolacga InjectionGa-68-Dolacga InjectionGa 68-Dolacga Injection
Beyond the preview
Go deeper on Ga68-Dolacga.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Ga68-Dolacga.